ImmunityBio & NantKwest Begin Dosing in Global Trials for COVID-19 Vaccine
08 Mar 2021 //
BUSINESSWIRE
ImmunityBio and NantKwest Announce FDA Authorization to Study hAd5 T-Cell
11 Feb 2021 //
BUSINESSWIRE
NantKwest, ImmunityBio Announce Positive Interim Data on Survival Rates
13 Jan 2021 //
PRESS RELEASE
CytRx Comments on Proposed Combination of ImmunityBio and NantKwest
22 Dec 2020 //
BUSINESSWIRE
CytRx Comments on Proposed Combination of ImmunityBio and NantKwest
22 Dec 2020 //
BUSINESSWIRE
CytRx Comments on Proposed Combination of ImmunityBio and NantKwest
22 Dec 2020 //
BUSINESSWIRE
CytRx Comments on Proposed Combination of ImmunityBio and NantKwest
22 Dec 2020 //
BUSINESSWIRE
2 Nants become one as Soon-Shiong merges NantKwest, ImmunityBio
21 Dec 2020 //
FIERCEBIOTECH
ImmunityBio, NantKwest Announce Positive Interim Ph1 Safety Data
10 Nov 2020 //
PRESS RELEASE
Patrick Soon-Shiong steps down as CEO NantKwest, a linchpin `Cancer Moonshot`
28 Oct 2020 //
ENDPTS
NantKwest Names Richard Adcock Chief Executive Officer
26 Oct 2020 //
PRESS RELEASE
ImmunityBio, NantKwest dose first patient in Phase I Covid-19 vaccine trial
22 Oct 2020 //
PHARMACEUTICAL-TECHNOLOGY
NantKwest, ImmunityBio Add Third-Line Cohort to Phase 2 Pancreatic Cancer Trial
06 Oct 2020 //
BUSINESSWIRE
NantKwest Announces FDA Authorization of IND Application for MS Cell Product
18 May 2020 //
BUSINESSWIRE
NantKwest and ImmunityBio to Initiate a Phase 2 Study of Immunotherapy
15 May 2020 //
BUSINESSWIRE
NantKwest and ImmunityBio Announce Therapeutics and Vaccines for Combatting
14 Apr 2020 //
NANTWEST
NantKwest doses first patient in Merkel cell carcinoma therapy trial
20 Mar 2020 //
CLINICALTRIALSARENA
NantKwest rockets on promising pancreatic cancer data
16 Jan 2020 //
PM LIVE
After a single patient drives a big stock surge
15 Jan 2020 //
STAT
NantKwest and ImmunityBio Announce Complete Response in Pancreatic Cancer
14 Jan 2020 //
BUSINESS WIRE